Atopix Therapeutics Limited is a clinical stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma. The company is developing a novel class of oral anti-Th2 therapies, called CRTH2 antagonists. Our lead candidate, OC459, is currently being studied in a Phase 2 proof-of-concept study to evaluate the effect of OC459 in patients with severe asthma who have persistent airway eosinophilia, despite treatment with high doses of inhaled corticosteroids; and a Phase 2a study of the response of asthmatics treated with OC459 to rhinovirus infection (common cold); and a Phase 3 clinical trial of patients with moderate persistent eosinophilic asthma in Russia. Our second cadidate, ATX2417, is undergoing a Phase 1 human safety study.